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Antibiotics have significant and long-lasting impacts on the intestinal microbiota
and consequently reduce colonization resistance against Clostridium difficile infection
(CDI). Standard therapy using antibiotics is associated with a high rate of disease
recurrence, highlighting the need for novel treatment strategies that target toxins, the
major virulence factors, rather than the organism itself. Human monoclonal antibodies
MK-3415A (actoxumab–bezlotoxumab) to C. difficile toxin A and toxin B, as an emerging
non-antibiotic approach, significantly reduced the recurrence of CDI in animal models
and human clinical trials. Although the main mechanism of protection is through direct
neutralization of the toxins, the impact of MK-3415A on gut microbiota and its restoration
has not been examined. Using a CDI murine model, we compared the bacterial
diversity of the gut microbiome of mice under different treatments including MK-3415A,
vancomycin, or vancomycin combined with MK-3415A, sampled longitudinally. Here, we
showed that C. difficile infection resulted in the prevalence of Enterobacter species. Sixty
percent of mice in the vehicle group died after 2 days and their microbiome was almost
exclusively formed by Enterobacter. MK-3415A treatment resulted in lower Enterobacter
levels and restoration of Blautia, Akkermansia, and Lactobacillus which were the core
components of the original microbiota. Vancomycin treatment led to significantly lower
survival rate than the combo treatment of MK-3415A and vancomycin. Vancomycin
treatment decreased bacterial diversity with predominant Enterobacter and Akkermansia,
while Staphylococcus expanded after vancomycin treatment was terminated. In contrast,
mice treated by vancomycin combined with MK-3415A also experienced decreased
bacterial diversity during vancomycin treatment. However, these animals were able
to recover their initial Blautia and Lactobacillus proportions, even though episodes of
Staphylococcus overgrowth were detected by the end of the experiments. In conclusion,
Džunková et al. Clostridium Antitoxin Antibodies Normalize the Microbiome
MK-3415A (actoxumab–bezlotoxumab) treatment facilitates normalization of the gut
microbiota in CDI mice. It remains to be examined whether or not the prevention
of recurrent CDI by the antitoxin antibodies observed in clinical trials occurs through
modulation of microbiota.
Keywords: Clostridium difficile infection, antibiotics, Bayesian networks, C. difficile toxin antibody, 16S rDNA
amplicon sequencing, MK-3415A, actoxumab and bezlotoxumab, immune therapy
INTRODUCTION
Clostridium difficile infection (CDI) has become the leading
recognized cause of nosocomial infectious diarrhea in the
developed world and with increased incidence and mortality
rates in recent years (Evans and Safdar, 2015). Antibiotics have
significant and long-lasting impacts on the intestinal microbiota
and consequently reduce colonization resistance against CDI.
Although antibiotic usage is amajor risk factor for acquiring CDI,
the standard care in clinics still remains the use of antibiotics
(metronidazole or vancomycin). Significant portion of CDI
patients treated with metronidazole or vancomycin will suffer a
recurrence after treatment is discontinued; many of these will
have multiple recurrences (Kelly and LaMont, 2008; O’Horo
et al., 2014). Given the increasing CDI incidence and severity as
well as high rate of disease recurrence after standard therapy, it is
clear that current approaches to disease prevention and treatment
are inadequate and that new non-antibiotic approaches are sorely
needed (Lowy et al., 2010; Evans and Johnson, 2015; Lee et al.,
2016).
It is already known that the normal fecal microbiome
provides a barrier against C. difficile, and that antibiotic therapy
weakens or disrupts this barrier allowing colonization. The
idea that restoration of the gut microbiota is necessary to
prevent recurrence is supported by an ∼90% success rate of
fecal microbiota transplantation (FMT; Seekatz et al., 2015), and
significant recovery of diversity and community membership
has been observed following FMT treatment for recurrent CDI
(Hamilton et al., 2013; Song et al., 2013; Seekatz et al., 2014).
Specific microbiota-derived characteristics associate with disease
severity and recurrence have been demonstrated (Seekatz et al.,
2016), although the precise composition of such a protective
barrier is not yet known (Gerding and Johnson, 2010).
Therefore, emerging CDI therapies are focused on limiting
further perturbation of the colonic microbiota and/or restoring
the microbiota to its pre-morbid state, reducing colonization of
gut by pathogenic C. difficile and bolstering the host immune
response against its toxins (Kociolek and Gerding, 2016). As an
emerging non-antibiotic therapy, human monoclonal antibodies
MK-3415A (actoxumab–bezlotoxumab) target C. difficile toxins,
themajor virulence factors ofC. difficile, rather than the organism
itself. Actoxumab (formerly known as MK-3415, GS-CDA1,
and MDX-066) and bezlotoxumab (formerly known as MK-
6072, MBL-CDB1, and MDX-1388) target toxin A and toxin
B, respectively. MK-3415A, the combination of actoxumab–
bezlotoxumab, significantly reduced the recurrence of CDI in
animal models (Hernandez et al., 2015; Yang et al., 2015; Zhang
et al., 2015) and human clinical trials (Lowy et al., 2010),
although in phase III trial co-administration with actoxumab
did not provide additional benefit. Although the main known
mechanism of protection is through direct neutralization of the
toxins (Hernandez et al., 2015; Yang et al., 2015), the impact of
MK-3415A on gut microbiota and its restoration has not been
examined.
One potential mechanism for reduced recurrence with anti-
toxin therapy is colonic toxin neutralization, thereby preventing
harmful toxin effects and leading to a curative restoration of
a healthy microbiome. Therefore, we hypothesize that MK-
3415A exerts its protective effect against CDI recurrence by
facilitating the restoration of the normal microbiota, in opposite
to the negative effects of standard antibiotic treatments such as
vancomycin. To test this hypothesis, we longitudinallymonitored
the dynamics of gut microbial profiles of mice that were infected




The murine CDI model was done as previously described (Chen
et al., 2008). MK-3415A or vehicle was given to clindamycin-
exposed mice 1 day prior to C. difficile inoculation (day −1)
at a sub-lethal dose. Mice that developed severe CDI were
sacrificed and cecal contents were collected. The antibody group
(n = 10) has been treated with MK-3415A (250 µg actoxumab
and bezlotoxumab each, Merck Inc.) 1 day before C. difficile
infection. The vancomycin group has been treated with oral
vancomycin (50mg/kg) during the days 0–4. The last group
contained mice (n = 10) treated with the antibody (on day 2)
and with vancomycin (days 0–4) at the same doses as above.
There was also a control mice group treated by a vehicle (n =
10). Individual mouse stool samples were collected on days −1,
0, 2, 4, 6, 8, 10, 14, 16, and 20 (depending on survival or disease
status) as shown in the Figure 1. In total, 183 fecal samples
were processed. Survival rate and weight as development signs
of CDI were recorded from the day 0 to the day 28. All animal
experiments were performed in accordance with the guidelines
of the IACUC committee of Beth Israel Deaconess Medical
Center.
DNA Extraction
The mouse stool samples (about 100 µl) were re-suspended
in 1ml of phosphate-buffered saline (PBS), vortexed rigorously
and let to pellet on the bench for about 30min. The upper
part was transferred to fresh 1.5ml tubes and centrifuged at
13,000 g for 5min. The bacterial pellet was washed twice with
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 2 October 2016 | Volume 6 | Article 119
Džunková et al. Clostridium Antitoxin Antibodies Normalize the Microbiome
FIGURE 1 | Mice survival rate of the four experimental groups. Time-points in which the fecal samples were collected are marked by colored dots above the
graph. The days of antibiotic treatment and antibody administration are also marked above the graph as explained in the legend.
PBS and finally resuspended in 1ml of PBS. An aliquot (220µl)
of the superior part was mixed with 350 µl of lysozyme (at
conc. 10mg/ml) and incubated 30min at 37◦C. Then 30 µl of
sodium dodecyl sulfate (conc. 10%) and 1.6 µl of proteinase K
(conc. 50mg/ml) was added and incubated for 60min at 50◦C.
Afterwards, 100µl 5MNaCl and 80µl cetyl trimethylammonium
bromide (10% of CTAB in NaCl) was added, the tubes were
vortexed rigorously and incubated for 15min at 65◦C. DNA
purification was performed by addition of 700 µl of phenol
followed by shaking for 2min and centrifugation at 13,000 g
for 3min. The upper part was transferred to a new tube and
mixed with 700 µl of chloroform and again shaken for 2min
and centrifuged. The upper part was mixed with 220 µl of
5 M NH4-acetate and 1 µl of glycogen. Afterwards, 500 µl
of isopropanol was added, the tubes were mixed by inverting
up and down and incubated at −80◦C for 2 h. Afterwards,
the tubes were centrifuged at 13,000 g for 45min at 4◦C. The
supernatant was discarded and the pellet was washed by addition
of 500 µl 70% ethanol and centrifugation for 10min. The
supernatant was again discarded and the pellet was let to dry
out at room temperature and finally resuspended in 100µl
of water.
16S rRNA Gene Amplification and
Sequencing
The regions V3 and V4 of the 16S rDNA gene were amplified
according to Klindworth et al. (2013). The PCR mix contained:
31.75 µl water, 4 µl dNTPs 2.5mM each, 0.25µl ExTaq
polymerase 5 U/µl (Takara, Ref. RR001A), 5 µl ExTaq buffer
10x, 2µl of 10mM 16S rDNA forward primer (5′-TCG TCG
GCA GCG TCA GAT GTG TAT AAG AGA CAG CCT ACG
GGN GGC WGC AG-3′), 2 µl of 10mM 16S rDNA reverse
primer (5′-GTC TCG TGG GCT CGG AGA TGT GTA TAA
GAG ACA GGA CTA CHV GGG TAT CTA ATC C-3′), and
5 µl DNA. PCR conditions: initialization step at 94◦C for
2min, 25 cycles of 94◦C for 30 s, 54◦C for 30 s, 72◦C for
30 s, and the final elongation at 72◦C for 10min. The PCR
reactions were purified by NucleoFast 96 PCR purification plates
(Machinery-Nagel, Ref. 743100.10) and finally resuspended in
50 µl water. The purified PCR reactions were multiplexed
using Nextera XT library preparation kit (Illumina, Ref. FC-131-
1096) and prepared for sequencing on MiSeq Illumina platform
according to the manufacturer’s instructions (Illumina, Ref. MS-
102-3001).
Sequence Processing
Sequence quality assessment was carried out by using PRINSEQ
program (Schmieder and Edwards, 2011). Sequences of length
<200 nt have not been considered; 5′ trimming was performed
cutting out nucleotides with a mean quality <30 in 20 bp
windows. Eventual chimeric 16S amplicons have been removed
by USEARCH program (Edgar, 2010). The sequences have
been deposited in European Nucleotide Archive database with
study accession number PRJEB10920. Obtained sequences were
clustered to form operational taxonomic units (OTUs) by CD-hit
program at 0.95 similarity level (Li and Godzik, 2006) and they
were associated with their taxonomic classification obtained by
RDP_classifier (boostrap cut-off 0.8) program from Ribosomal
Database Project (Cole et al., 2009). The bacterial OTUs that
constituted for <183 read (1 read/sample on average) have been
joined into under-represented OTUs item.
Bacterial Diversity Analysis
The Shannon diversity index was calculated using R package
“vegan” (Oksanen et al., 2006). If all abundance is concentrated
to one type, and the other types are very rare (even if there are
many of them), Shannon index approaches zero. The changes
in Shannon index along the time was analyzed by Wilcoxon
test (p < 0.05) comparing the consecutive time-points of the
experimental groups. In addition, the values of the day with the
lowest bacterial diversity were compared with the last collected
day of each experimental group.
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Canonical Correspondence Analysis
The canonical correspondence analysis (CCA) was used for the
ordination of the 183 samples. Using the “envfit” function from
“vegan” R package, the bacterial composition (OTUswith average
proportion >0.02%) was tested for fitting on the time-points
of the experimental groups categories. Mice were allocated in
different experimental cages, thus the influence of cage on the
microbiota was tested, too; for this test the samples were divided
into corresponding experimental groups and time-points and a
CCA using the “envfit” function has been carried out.
Comparison of the Experimental Groups at
Their Common Time-Points
The percentage proportions of OTUs (OTUs with average
proportion >0.02%) have been compared by Wilcoxon test
(significance level at p < 0.05) in the following experimental
groups at their common time-points.
Longitudinal Analysis of OTUs Proportion
A significant (p < 0.05) increase/decrease of proportion of each
OTU among two consecutive time-points was analyzed for each
individual mice by “edgeR” package (Robinson et al., 2010),
which includes Benjamini-Hochberg correction (all considered
OTUs were taken into this analysis). Only significant variations
confirmed by at least 80% of mice were considered.
Correlations among Bacterial OTUs, Body
Weight and Experimental Time
Bayesian networks constructed using R package “bnlearn”
(Scutari, 2010) were used to find statistically significant
correlations (Spearman correlation >0.3 and <−0.3) among
the bacterial OTUs (average proportion >0.02%), experimental
time-points (after day −1) and the mice body weight. Separate
networks were constructed for each experimental mice group.
The connecting arcs of such a network represent mutual
associations (not causality). From a Bayesian network, a subset
called Markov blanket can be extracted determining which
bacterial taxa influences the selected nodes (Vazquez-Castellanos
et al., 2015). In our case, the nodes corresponding to the body
weight and time-points were dissected in order to describe
the most important associations within each experimental
group.
RESULTS
Ninety percent of mice in the MK-3415A antibody group
(A.group) were symptomless during the whole experimental
duration (Figure 1). The antibody + vancomycin group
(A+Vanc.group) had the similar final survival rate of 80%. In
contrast, in vancomycin group (Vanc.group) death occurred
in 60% of mice; their life span (50% of mice surviving) was
10 days. The vehicle group had life span of only 4 days. The
collected samples of the vehicle group were divided into two
groups: the mice with immediate death (vehicle dead group—
VehD.group) and the survived mice (vehicle alive group—VehA.
group).
16S rDNA amplicons sequencing produced an average of
65,658.78 ± 40,677.07 sequences per sample. The dataset
contained in total 12,316,896 sequences, which were clustered
into 11,044 OTUs. The bar-plots representing the bacterial
composition for all 183 samples are shown in the Figure S1.
Day −1 refers to the day of clindamycin administration
prior to C. difficile infection and was considered as a baseline
of the mice microbiome after antibiotic mixture exposure. The
microbiome of all experimental groups had the highest Shannon
diversity index on day −1 (1.57 ± 0.38, Figure 2), which
significantly decreased on day 0 (the day of C. difficile infection,
1 day after clindamycin administration). The diversity index
decreased significantly on day 0 (p< 0.01 in all groups, Figure 2),
with the bacterial diversity concentrating on a few of the most
prevalent OTU. In the following days, the Shannon index differed
between experimental groups. For example, in the vancomycin-
treated experimental groups (Vanc.group and A+Vanc.group)
low bacterial diversity was detected on day 4, but it returned to
the initial values after the vancomycin treatment finalized (on the
day 8).
Afterwards, we analyzed the longitudinal changes in the
proportions of the bacterial OTUs. Bacterial composition was
significantly influenced by the type of treatment and the
experimental time (p < 0.001, Figure 3A). In contrast, it was
FIGURE 2 | Shannon microbial diversity index. The values for each sample are visualized as colored dots according to their experimental groups (red, gray, blue,
green, and orange). The microbiome of all experimental groups had the highest Shannon diversity index on day −1 and decreased significantly (p < 0.01) on day 0.
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FIGURE 3 | Microbial composition of the experimental groups. (A) The canonical correspondence analysis (CCA). The time-points of the experimental groups
had significant influence on the microbial composition. Each dot represents the total microbial composition of one sample. The names of bacterial OTUs with the
significant influence (p < 0.01) on the ordination of samples in this CCA plot are shown, it was mostly driven by tree bacterial groups (Klebsiella/Enterobacter,
Blautia/Akkermansia/Allobaculum/Lactobacillus/Barnesiella, and Staphylococcus). The numbers in the CCA plot refer to the collected days, they are colored
according to the experimental group colors (red, gray, blue, green, orange) and their coordinates in the plot are given by the direction of their influence on the
ordination of the samples. (B) Longitudinal comparison of the proportion of bacterial OTUs in pairs of two consecutive time-points. The increasing/decreasing
direction of the arrows mean that the proportion of that particular OTU had significant (p < 0.05) fold-change increase/decrease between the inquired consecutive
time-points. The most important changes in bacterial proportions occurred on the days 0 and 4 corresponding to the treatment changes. (C) Comparison of the
OTUs proportions in the common time-points of the experimental groups. Significant differences are marked by asterisks (*p < 0.05, **p < 0.01, ***p <0.001),
box-plot colors refer to the experimental groups. The most important differences between groups were detected on day 0 and 4.
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confirmed that grouping of mice by cages did not have significant
influence on the microbiota composition (p > 0.05).
The most typical representative OTUs of the initial
microbiome on day −1 in all experimental groups were
Akkermansia, Blautia, Lactobacillus, Allobaculum, and
Barnesiella OTUs (Figure 3). On day 0, drastic changes in
bacterial composition occurred, these OTUs were replaced
almost exclusively by Enterobacter and Klebsiella in all
experimental groups. Proportions of other OTUs evolved
differently depending on their experimental group. For
example, Lactobacillus proportion significantly decreased
(p < 0.05) on day 0 in all experimental groups except A.group
(Figure 3B). A.group quickly recovered its initial proportions of
Blautia and Akkermansia. In contrast, the high proportions of
Enterobacter/Klebsiella (OTU 21) persisted in the VehA.group
until the last experimental day and its microbiome did not
recover to its initial composition.
The microbiome of the vancomycin-treated groups
(Vanc.group and A+Vanc.group) was modulated differently
from the antibiotic-free groups (Figure 3). On day 4, the
microbiomes of vancomycin-treated groups were almost
exclusively formed by Enterobacter/Klebsiella and Akkermansia.
The amount of Blautia and Lactobacillus were significantly
reduced, while the amount of Akkermansia was significantly
increased in the vancomycin groups in comparison of those
without vancomycin treatment (p < 0.05, Figure 3C). After
termination of vancomycin treatment, the microbiome
dominated by Enterobacter/Klebsiella and Akkermansia
was replaced by one with higher proportions of Blautia,
Staphylococcus, Turicibacter, and Enterococcus. A.group also
contained low proportions of Staphylococcus on day 10. However,
the proportion of Staphylococcus on days 8 and 10 in Vanc.group
was significantly higher (p= 0.006).
Due to the short life span of the mice in the Vanc.group
(the last sample collection was on day 8), it was not
possible to compare microbiome patterns after vancomycin
treatment with the microbiome of A+Vanc.group. The final
experimental days of A+Vanc.group (days 10–20) had oscillating
proportions of Staphylococcus (significantly decreased on days
12–16 and increased on day 20) and a decreasing trend
of Enterobacter/Klebsiella resembling the original microbiome
composition (Figure 3).
The Bayesian networks based on microbial frequencies of
all samples in all experimental groups (Figure 4A) showed that
the Enterobacter/Klebsiella OTU 21 correlated negatively with
Akkermansia, Allobaculum, Barnesiella, Blautia, Lactobacillus,
Staphylococcus, and with the mice body weight.
When the Bayesian networks were analyzed individually for
each experimental group (Figure 4B), we found that the body
weight correlates positively with different OTUs, depending
on the applied treatment. The body weight in the A.group
correlated negatively with Enterobacter/Klebsiella. In contrast,
the body weight of the antibiotic treated groups (Vanc.group
and A+Vanc.group) correlated negatively with Blautia and
Lactobacillus. This was not expected, because Enterobacter/
Klebsiella and Blautia+Lactobacilluswere antagonists. One likely
explanation for this observation was that after the termination of
vancomycin treatment the mice body weight of the vancomycin
groups significantly increased (p < 0.01), but the proportions
of Blautia and Lactobacillus decreased, as they were replaced by
Enterobacter/Klebsiella and Akkermansia (day 4).
DISCUSSION
Human monoclonal antibodies MK-3415A to C. difficile toxin
A and toxin B, as passive immune therapy, have been shown
to significantly reduce the recurrence of CDI in human clinical
trials (Lowy et al., 2010). Although the main mechanism of
protection is through direct neutralization of the toxins (Yang
et al., 2015), the impact of MK-3415A on gut microbiota and its
restoration has not been examined. In this study we examined
the impact of antitoxin antibodies on the gut microbiota and
its restoration. Our results demonstrated that MK-3415A
significantly influences the taxonomic composition of the
gut microbiota. Clindamycin pre-exposure and C. difficile
infection produced a decrease in microbial diversity caused by
an overgrowth of Enterobacter/Klebsiella species. Microbiome
of mice succumbed to C. difficile infection was characterized
by high proportions of Enterobacter/Klebsiella species, while
the mice treated by MK-3415A were able to reconstitute
their original microbial composition formed mainly by
Lactobacillus, Akkermansia, and Blautia. Vancomycin treatment
resulted in decreased bacterial diversity and overgrowth of
Enterobacter/Klebsiella and Akkermansia species. This was also
observed in mice with combined treatment of vancomycin and
MK-3415A, confirming the strong effect of vancomycin on
microbiota. Vancomycin temporarily attenuated the disease,
but with an increase of body weight observed right after the
vancomycin treatment in the vancomycin and vancomycin +
MK-3415A mice groups. However, mice treated by vancomycin
died shortly after the treatment was terminated. In contrast, mice
treated with vancomycin + MK-3415A were able to recover
the proportion of Blautia and Lactobacillus with much higher
survival rate.
Akkermansia was one of the most prevalent genera observed
in the mice microbiota before clindamycin pre-treatment
and C. difficile infection. Akkermansia is an intestinal mucin-
degrading bacterium (Derrien et al., 2004). However, Salmonella
mice infection models showed that the excessive mucin
degradation by Akkermansia may contribute to inflammatory
bowel diseases because mucin degradation facilitates the
access of luminal antigens to the intestinal immune system
(Ganesh et al., 2013). It is important to mention, that the
original microbiota of our experimental mice before C.
difficile infection contained also high amounts of Lactobacillus
and Blautia. Lactobacillus species are often included in the
probiotics or fecal transplantation mixtures due to their
anti-inflammatory properties (Mohamadzadeh et al., 2011).
Blautia has been associated with whole grain diet (commonly
used for experimental mice feeding) and coincided with
improvements in host physiological measures (Martinez
et al., 2013). Vancomycin treatment in our study significantly
decreased the proportions of Lactobacillus and Blautia, while the
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FIGURE 4 | Bayesian networks of correlations of the bacterial OTUs. Positive (red arcs) and negative (blue arcs) correlations (Spearman correlation >0.3 and
<−0.3) between bacterial OTUs visualized as a Bayesian network using R package “bnlearn.” The connecting arcs of the network represented mutual associations
(not causality). Separate networks were constructed for all samples combined together (A) and also separated according to the experimental group (B). Separate
networks for each experimental group in the (B) contain also correlations with mice body weight and experimental time. The bold arcs in the (B) connect the bacterial
OTUs with have the most important associations to the body weight and experimental time (so called dissection of Markov blankets). VehD.group was excluded from
the analysis due to the low number of time-points.
high amounts of Akkermansia persisted. In addition, the high
proportion of Akkermansia after vancomycin treatment was
accompanied by a high proportion of Enterobacter/Klebsiella.
It might suggest that if high proportion of Akkermansia is
accompanied with high proportions of Lactobacillus and Blautia,
its inflammatory effect of Akkermansia might be attenuated.
However, this is still very speculative and remains to be further
examined.
The overgrowth of Enterobacter/Klebsiella after clindamycin
pre-treatment is a reflection of its natural resistance to this
antibiotic (Nyberg et al., 2007). Similar observations of increase
of Enterobacter and decrease of Barnesiella after clindamycin pre-
treatment and C. difficile inoculation in mice models has been
reported (Buffie et al., 2012).
Staphylococcus is commonly sensitive to clindamycin (Levin
et al., 2005) and therefore it was suppressed until the
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clindamycin effect completely disappeared. Interestingly, after
the termination of vancomycin treatment, Staphylococcus and
Enterococcus expanded to the levels higher than those at the
beginning of the experiment or in the normal microbiota of the
antibody group. Staphylococcus and Enterococcus can be found
in human microbiota, but they are opportunistic pathogens
which could take advantage of the decreased bacterial diversity
due to vancomycin treatment to initialize their colonization
(Hiramatsu, 2001; Kaslow and Shiver, 2011; Stecher et al.,
2013). Indeed, it was well-documented that antibiotic treatment
of C. difficile infections leads to the emergence of additional
infections by bacteria resistant to these antibiotics (Willems et al.,
2005).
Mice group treated with vancomycin and MK-3415A also
experienced a reduction of bacterial diversity during the
vancomycin treatment. However, these mice were able to recover
their initial Blautia and Lactobacillus proportions. It is important
to mention that the episodes of Staphylococcus overgrowth were
detected during the final experimental days despite the MK-
3415A administration. It might indicate that in opposite to
MK-3415A alone, MK-3415A plus vancomycin may increase
the risk of the infection by other opportunistic pathogens and
C. difficile recurrence would persist due to the enormous ability
of vancomycin to perturb the gut microbiome.
In conclusion, MK-3415A facilitates normalization of the
gut microbiota in antibiotic-treated, C. difficile-challenged mice
compared to the untreated animals. In contrast, vancomycin
perturbs the gut microbiome, causes the overgrowth of potential
opportunistic pathogens and reduces the amounts of anti-
inflammatory bacterial species. Despite significant microbiome
perturbations caused by vancomycin, antitoxin antibodies in
combination with vancomycin still preserves its ability to
normalize the gut microbiota and to improve disease outcome.
This study may help explain the beneficial effect of MK-3415A
observed in animal models and in clinical trials of CDI. The
difference of impact on human or animal microbiota between the
individual components (actoxumab vs. bezlotoxumab) is worthy
of further investigation.
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